MicroRNA Market Size

MicroRNA Market Analysis

The microRNA market is projected to register a CAGR of 15.6% during the forecast period.

• The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. In addition to vaccinations against SARS-CoV-2 infection that had been approved, microRNAs were found to be a potential alternative for combating this new virus. 
• According to the article published in March 2021 in PubMed, various microRNAs bind to the SARS-CoV-2 genome and limit its post-transcriptional expression, reducing the severity of COVID-19 disease. In addition, among all miRNAs, miR-21-3p was found to have the best binding to the human coronavirus genome. In the post-pandemic situation, the market is expected to witness growth due to the increase in chronic diseases that require novel therapies and the rise in advancements in microRNA technologies.
• The factors propelling the growth of the microRNA market are the increasing prevalence of chronic diseases, the advancement and adoption of next-generation sequencing methods and their applications in various fields, and the increasing adoption of microRNA as a biomarker. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, etc., and rare diseases are the key factors driving the growth of the market over the forecast period. 
• For instance, according to the American Cancer Society 2023 Statistics, 1.9 million new cancer cases are anticipated to be recorded in the United States in 2023, a rise from 1.8 million in 2021. In addition, the adoption of microRNA in cancer treatment is expected to be aided by extensive research activities. For instance, as per the article published in February 2022 in PubMed, the identification and characterization of new cancer-relevant miRs may be used to facilitate patient diagnosis and prognosis of different tumors. Moreover, miR profiles can define relevant tumoral subtypes. Thus, the study of tumors with the aid of microRNA is expected to be one of the major factors boosting market growth.
• Moreover, key players have entered into several strategic initiatives such as mergers, acquisitions, and partnerships to expand their product availability across the globe. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target microRNAs. 
• Similarly, in February 2021, Aurora Science, an Italian biotech investment company, funded USD 22.46 million to InteRNA Technologies for developing microRNA. InteRNA Technologies is a clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in the initiation and progression of human diseases, with a focus on cancer. These microRNA compounds, chosen through its top-tier microRNA discovery and functional validation technology platform and equipped with a third-generation drug delivery formulation, can launch a coordinated anti-cancer assault by simultaneously interacting with several signal transduction targets.
• Thus, due to the increase in research and development activities, the surge in investments, and the growing burden of chronic disease that utilizes the application of microRNA for therapies, the studied market is expected to witness growth over the forecast period. However, the safety and toxicity issues of microRNAs are likely to hinder the growth of the market over the forecast period.